OR WAIT null SECS
April 14, 2023
The acquisition of Cell Systems will bolster AnaBios’ portfolio of human tissue and cells for use in drug discovery.
April 05, 2023
Sartorius’ acquisition of Polyplus is designed to strengthen its cell and gene therapy capabilities.
March 30, 2023
CDMO Exothera and biotech company Remedium are joining forces to scale up the manufacturing process for Remedium’s lead gene therapy candidate for treating osteoarthritis.
Takeda plans to build a new facility in Osaka, Japan, for the manufacture of plasma-derived therapies.
March 21, 2023
Sanofi intends to cut its US list price for Lantus (insulin glargine injection) by 78% and cap out-of-pocket costs at $35 for all patients with commercial insurance.
BioNTech will receive an exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 mAb candidate for solid tumor indications.
March 17, 2023
Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.
Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.
The collaboration between Genuv and Celltrion will utilize Genuv's proprietary mouse platform for antibody discovery.
March 16, 2023
Pfizer will acquire all outstanding shares of Seagen for a total of $43 billion.